Anaplastic lymphoma kinase inhibitors.
作者： Ramona Crescenzo , Giorgio Inghirami
DOI: 10.1016/J.COPH.2015.05.010
关键词: Crizotinib 、 Clinical trial 、 Insulin receptor 、 Anaplastic lymphoma kinase 、 Biology 、 Chimera (genetics) 、 Food and drug administration 、 SUPERFAMILY 、 Cancer research
摘要: The anaplastic lymphoma kinase (ALK) gene is a member of the insulin receptor superfamily and it has been associated with more than twenty distinct chimera, including established drivers several human cancers. Multiple clinical trials have proven that pharmacological inhibition ALK signaling leads to remarkable improvement improves quality life ALK+ cancer patients. Crizotinib was first ALKi achieve approval from Food Drug Administration, although additional compounds are now moving into diversified trials.
sci-hub.se 参考文章(45)
Fujimoto J, Shiota M, Mori S, Yamamoto T, Satoh H, Semba T, Hyperphosphorylation of a Novel 80 kDa Protein-Tyrosine Kinase Similar to Ltk in a Human Ki-1 Lymphoma Cell Line, AMS3 Oncogene. ,vol. 9, pp. 1567- 1574 ,(1994)
Mark M Awad, Alice T Shaw, ALK Inhibitors in Non–Small Cell Lung Cancer: Crizotinib and Beyond Clinical advances in hematology & oncology. ,vol. 12, pp. 429- 439 ,(2014)
Tao Jiang, Caicun Zhou, [Treatment of patients with ALK gene rearranged non-small cell lung cancer after resistance to crizotinib]. Chinese Journal of Lung Cancer. ,vol. 18, pp. 69- 74 ,(2015) , 10.3779/10.3779/J.ISSN.1009-3419.2015.02.03
Sen Zhang, Frank Wang, Jeffrey Keats, Xiaotian Zhu, Yaoyu Ning, Scott D. Wardwell, Lauren Moran, Qurish K. Mohemmad, Rana Anjum, Yihan Wang, Narayana I. Narasimhan, David Dalgarno, William C. Shakespeare, Juan J. Miret, Tim Clackson, Victor M. Rivera, Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chemical Biology & Drug Design. ,vol. 78, pp. 999- 1005 ,(2011) , 10.1111/J.1747-0285.2011.01239.X
Paolo Vicini, Shinji Yamazaki, Justine L. Lam, Helen Y. Zou, Hui Wang, Tod Smeal, Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1. Journal of Pharmacology and Experimental Therapeutics. ,vol. 351, pp. 67- 76 ,(2014) , 10.1124/JPET.114.217141
Alana Dikopf, Kevin Wood, Ravi Salgia, A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients Expert Opinion on Drug Safety. ,vol. 14, pp. 485- 493 ,(2015) , 10.1517/14740338.2015.1007040
Denis Maillet, Isabelle Martel-Lafay, Dominique Arpin, Maurice Pérol, Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. Journal of Thoracic Oncology. ,vol. 8, ,(2013) , 10.1097/JTO.0B013E318288DC2D
Yael P Mossé, Megan S Lim, Stephan D Voss, Keith Wilner, Katherine Ruffner, Julie Laliberte, Delphine Rolland, Frank M Balis, John M Maris, Brenda J Weigel, Ashish M Ingle, Charlotte Ahern, Peter C Adamson, Susan M Blaney, Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study Lancet Oncology. ,vol. 14, pp. 472- 480 ,(2013) , 10.1016/S1470-2045(13)70095-0
Justin F. Gainor, Sai-Hong Ignatius Ou, Jennifer Logan, Lawrence F. Borges, Alice T. Shaw, The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. Journal of Thoracic Oncology. ,vol. 8, pp. 1570- 1573 ,(2013) , 10.1097/JTO.0000000000000029
Cheryl M Coffin, Ankita Patel, Sherrie Perkins, Kojo S J Elenitoba-Johnson, Elizabeth Perlman, Constance A Griffin, ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Modern Pathology. ,vol. 14, pp. 569- 576 ,(2001) , 10.1038/MODPATHOL.3880352